MD Anderson Cancer Center

Site:	MD Anderson Cancer Center	Go to their website
Address:	1505 Holcombe Blvd.
City:	Houston
State:	TX
Zip:	77030
Country:	USA

63 trials at this site

Phase	Trial [asc]	Trial Status	Site Status	Drug	NCT#
2	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Completed	Closed	Dovitinib	NCT01831726
1	DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	DS-6157a	NCT04276415
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib (ENEST)	Completed	Closed	Nilotinib	NCT00471328
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension	Completed	Closed	Nilotinib	NCT00488150
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
	Gastrointestinal Stromal Tumors (GIST) Registry	Completed	Closed	None	NCT00507273
1	IMC-A12 in Combination With Temsirolimus (CCI-779) in Patients With Advanced Cancers	Ongoing, but not recruiting	Closed	IMC-A12 + CCI-779	NCT00678769
1	Ipilimumab and Imatinib Mesylate in Advanced Cancer	Active, not recruiting	Closed	Imatinib + Ipilimumab	NCT01738139
2	Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors	Completed	Not yet activated	Linsitinib (OSI-906)	NCT01560260
1	Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer	Ongoing, but not recruiting	Closed	IMC-A12 + CCI-779	NCT00678223
2	Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes	Active, not recruiting	Closed	Durvalumab + Tremelimumab	NCT02815995
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
2	Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery	Terminated	Closed	Imatinib + Oblimersen	NCT00091078
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Active, not recruiting	Active, nor recruiting	Bezuclastinib plus Sunitinib	NCT05208047
2	Ph II Study of Perifosine Plus Gleevec for Patients With GIST	Completed	Closed	Imatinib + Perifosine	NCT00455559
1	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Active, not recruiting	Closed	INBRX-109 + Temozolomide	NCT03715933
1	Phase 1 Study of Intermittent OSI-906 Dosing	Ongoing, but not recruiting	Closed	Linsitinib (OSI-906)	NCT00514306
1/2	Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion	Recruiting	Active	MRTX1719	NCT05245500
2	Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.	Recruiting	Active	Regorafenib (SDH)	NCT06087263
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753

MD Anderson Cancer Center

63 trials at this site

First | Previous | Page 2 of 4 | Next | Last